Epidemiological, clinical, outcome and antibiotic susceptibility differences between PVL positive and PVL negative Staphylococcus aureus infections in Western Australia: a case control study by Peter Boan et al.
Boan et al. BMC Infectious Diseases  (2015) 15:10 
DOI 10.1186/s12879-014-0742-6RESEARCH ARTICLE Open AccessEpidemiological, clinical, outcome and antibiotic
susceptibility differences between PVL positive
and PVL negative Staphylococcus aureus infections
in Western Australia: a case control studyPeter Boan1*, Hui-Leen Tan1,2, Julie Pearson1,2, Geoffrey Coombs1,2, Christopher H Heath1
and James Owen Robinson1,2Abstract
Background: Panton Valentine Leukocidin (PVL) has been associated with invasive Staphylococcus aureus soft tissue
and pneumonic infections.
Methods: From September 2007 to January 2009 at Royal Perth Hospital we tested for the PVL gene in S. aureus
isolates from an invasive site, a suspected PVL-related soft tissue infection and all MRSA isolates. We could access
medical records for 141 PVL positive (PVL + ve) infections and compared these to a control group comprised of 148
PVL negative (PVL-ve) infections.
Results: In the PVL + ve group 62 isolates were MRSA (48 were ST93-MRSA-IV) and 79 isolates were methicillin-sensitive S.
aureus, and in the PVL-ve group 56 were MRSA (50 were WA-MRSA strains) and 92 were methicillin-sensitive S. aureus.
We found the presence of PVL to be significantly associated with younger age, aboriginality, intravenous drug use,
community acquisition, shorter length of hospital stay and lower mortality at 1 year. Overall PVL + ve infections more
often required surgical intervention (73.0% versus 44.6%, p < 0.001) and were less often polymicrobial (8.5% versus 41.2%,
p < 0.001). PVL + ve isolates were more often susceptible to clindamycin (87.9% versus 73.0%, p = 0.002).
Conclusions: This study demonstrates that PVL + ve infections are associated with a distinct clinical picture,
predominantly pyogenic skin and soft tissue infections often requiring surgery, disproportionately affecting
patients who are younger, indigenous or with fewer health-care risk factors.
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Staphylococcus aureus is a common human pathogen
which causes a wide variety of infections. Over the past
decades, S. aureus epidemiology has dramatically chan-
ged with the appearance of methicillin resistant strains
in the community (CA-MRSA), when such strains had
previously only been described in hospitals. Since its ini-* Correspondence: Peter.Boan@health.wa.gov.au
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the world accounting for nearly 70% of S. aureus recov-
ered from patients with skin and soft tissue infections at-
tending an emergency department in the United States
[2]. Although diverse clones are responsible for the
emergence of CA-MRSA world-wide, the major global
clones harbour the Panton-Valentine leukocidin (PVL)
[3], a pore-forming toxin that disrupts host cell mem-
branes and which is associated with recurrent boils [4],
necrotising fasciitis [5] and necrotising pneumonia [6];his is an Open Access article distributed under the terms of the Creative
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carriage [7]. Naturally PVL has been well studied in
CA-MRSA though our study contributes also to the
expanding data on PVL in methicillin sensitive S. aureus
(MSSA), and describes aspects of local Western Australian
S. aureus epidemiology, clinical outcomes, antimicrobial




Royal Perth Hospital is an adult tertiary centre with a
955-bed capacity. The Australian Collaborating Centre
for Enterococcus and Staphylococcus Species (ACCESS)
Typing and Research performs PVL testing on (a) all S.
aureus grown from sites of invasive disease (e.g. tissue,
bone/joint, blood), (b) S. aureus from some skin/soft
tissue specimens (where there is some suggestion of ag-
gressive infection such as abscess formation, determined
by the microbiology scientist’s interrogation of the clin-
ical notes and specimen description on the laboratory
request form), (c) all MRSA isolates including nasal and
skin colonisation swabs. For this study we excluded S.
aureus colonisation, defined as S. aureus growth without
need for surgery or antimicrobial therapy, and duplicate
isolates from the same patient were not included. We
collated data from all 170 PVL + ve isolates between
September 2007 and January 2009. Medical records were
unavailable for 7 cases and 22 (13.5%) colonising isolates
were excluded, leaving 141 PVL + ve infections during
the 17 month period. Of 1,146 PVL-ve isolates during
the time period, 836 were MRSA cultured from nasal or
skin colonisation swabs (72.9%). From the remaining 310
cases to approximate numbers in the PVL + ve group, 148
PVL-ve S. aureus infections were selected as “controls” by
selecting every second isolate chronologically.
Demographics and co-morbidity data were collected
from the medical record, and all cause mortality at 30-
days and 1-year was determined from clinical informa-
tion systems data-linked to the Western Australian
Registry of Deaths. We recorded whether empirical
antibiotic choice was effective (defined if the isolate
was susceptible in vitro to any of the antibiotics pre-
scribed), empirical use of protein synthesis inhibitors
(lincosamide/linezolid), and lincosamide/linezolid use
within 3 days of isolate acquisition. Infection was de-
fined as “hospital acquired” if the isolate was collected
more than 48 hours after admission and symptoms
were not present on admission. “Healthcare associ-
ated” infection occurred in the community in the pres-
ence of at least one of the following three risk factors:
(a) in the past 12 months a history of surgery, hospi-
talisation, dialysis or residence in a long term care
facility, (b) presence of an invasive device at the timeof infection onset, (c) a history of MRSA infection
or colonisation. “Community acquired” infection oc-
curred in the community without any of the above risk
factors [8]. The study was approved by the Royal Perth
Hospital Ethics Committee. Patient informed consent
was waived in accord with guidelines of the National
Health and Medical Research Council of Australia for
a clinical audit [9].
Microbiological methods
S. aureus was identified using routine laboratory methods
(catalase-positive, tube coagulase-positive Gram-positive
cocci). Antibiotic susceptibilities were determined by disk
diffusion using CLSI methodology and breakpoints [10].
Methicillin resistance was determined by demonstrating
cefoxitin resistance. Genes encoding PVL were detected
with the nuclease (nuc) and mecA genes by an in-house
real time polymerase chain reaction (PCR) assay using the
Light Cycler 2.0 (Roche Diagnostics) as previously de-
scribed [11]. Briefly a single colony incubating for less
than 48 hours was first treated with lysostaphin, pro-
teinase K and tris buffer. Cell lysate was added to the
in-house PCR master mix containing 1× LightCycler
Master Hybridization Probes mixture (Roche Molecu-
lar Biochemicals), 5 mM MgCl2, 0.5 μM forward and
reverse primers and two FRET (Fluorescence Reson-
ance Energy Transfer) probes (0.2 μM) each for PVL,
mec and nuc genes. Two microlitres of sample was
added to 18 microlitres of mastermix. We performed
45 cycles of PCR with 3 channel detection of the gene
products followed by melt curve analysis. Six controls
were used for each PCR run: MRSA PVL negative,
MSSA PVL positive, MR coagulase negative Staphylo-
coccus, MS coagulase negative Staphylococcus, a mu-
tant MRSA PVL negative strain (which demonstrates
low efficiency nuc PCR), and a negative control. A
positive result for PVL, mec or nuc required exponen-
tial increase in fluorescence within 40 PCR cycles and
a characteristic melting temperature. All MRSA and no
MSSA isolates were typed by antibiogram, Christensen’s
urea broth, and previously described coagulase gene
PCR-Restriction Fragment Length Polymorphisms assay
and contour clamped Homogenous Electric Field
Electrophoresis [12]. Multi Locus Sequence Typing and
Staphylococcal Chromosomal Cassette mec typing by
PCR were performed on some isolates according to
prior description [13].
Statistical methods
Data was examined in IBM SPSS Statistics version 19
(SPSS Inc., Chicago, IL, USA). Continuous variables
were examined by the t-test or Mann–Whitney U-test as
appropriate and categorical variables by the Chi-Squared
or Fisher’s exact test as appropriate. Logistic regression
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For all statistical analysis a p-value <0.05 was considered
to be significant.
Results
Patients with PVL + ve S. aureus infections compared to
the control group were younger (median age 37 vs
58 years, p < 0.001), more often male (72.3% vs 62.8%, p =
0.085), more commonly indigenous (34.0% versus 12.2%,
p < 0.001), more often intravenous drug users (16.3% vs
6.8% respectively, p = 0.011), but were less likely to have
haematological malignancy (0.0% vs 4.1%, p = 0.016) or a
solid tumour (1.4% vs 9.5%, p = 0.003). Long-term care
facility residents were rarely infected with PVL + ve
strains, being 1.4% of PVL + ve cases compared to 14.9%
of controls (p < 0.001). The majority of PVL + ve infections
were community acquired in contrast to the control group
which were often healthcare associated or hospital ac-
quired infections (Table 1).
Skin and soft tissue was the most common site of in-
fection in both groups, being significantly more common
in the PVL + ve compared to the PVL-ve group (81.6%
vs 63.5%, p < 0.001), and abscesses accounted for a larger
percentage of these infections in the PVL + ve group
versus controls (87.0% compared to 41.5% respectively,
p < 0.001). Bacteraemia occurred in 50 cases, of which
13 (26.0%) were PVL + ve (p < 0.001). Bone and joint in-
fections were the third most common site of infection
being less common in the PVL + ve than the control






Age (median) 37 58 <0.001
Male 102 (72.3) 93 (62.8) 0.085
Indigenous 48 (34.0) 18 (12.2) <0.001
Intravenous Drug Use 23 (16.3) 10 (6.8) 0.011
Haematological malignancy 0 (0) 6 (4.1) 0.016
Solid malignancy 2 (1.4) 14 (9.5) 0.003
Diabetes Mellitus 31 (22) 44 (29.7) 0.133
Immunosuppressive treatment 7 (5) 14 (9.5) 0.141
HIV positive 3 (2.1) 2 (1.4) 0.613
Pre-existing skin condition 4 (2.8) 4 (2.7) 0.945
Hospitalisation in the past year 50 (35.5) 92 (61.2) <0.001
Long term care facility resident 2 (1.4) 22 (14.9) <0.001
“Community acquired”
infection
87 (61.7) 35 (23.6) <0.001
“Healthcare associated”
infection
46 (32.6) 78 (52.7) <0.001
“Hospital acquired” infection 8 (5.7) 35 (23.6) <0.001
Number (%).(5.0%) lung infections were due to PVL + ve S. aureus
(4 empyema, 1 lung abscess, 2 pneumonia) compared to
3 (2.0%) due to PVL-ve S. aureus (2 pneumonia and one
empyema, p = 0.172). For 12 (8.5%) PVL + ve infections
another pathogen was grown from the same specimen
compared to 61 (41.2%) of the control group. This dif-
ference was most marked for skin and soft tissue infec-
tions though a trend was also seen in bloodstream and
bone/joint samples (Table 2).
Antimicrobial susceptibility results are shown in
Table 3. Of note, 87.9% of PVL + ve isolates tested sus-
ceptible (includes a negative D-test) to clindamycin
compared with 71.6% of the control isolates (p = 0.002).
Erythromycin and mupirocin susceptibility rates were
also higher for PVL + ve strains compared to controls.
Overall, only 80.1% of MRSA isolates were susceptible
to clindamycin (data not shown).
Queensland clone (ST 93-IV, n = 48) was the predom-
inant PVL + ve MRSA strain, with smaller numbers of
Western Samoan Phage Pattern strains (ST30-IV, n = 5),
USA 300 (ST8- IV, n = 4), WA1-MRSA strains (ST1-IV,
n = 3), Taiwan strain (ST59-VT, n = 1) and EMRSA-15
(ST22-IV, n = 1). For PVL-ve MRSA isolates, most
were WA-MRSA strains (WA-MRSA-1 [ST1- IV], WA-
MRSA-2 [ST78-IV], WA-MRSA-3 [ST5-IV], WA-MRSA-
75 [ST45-IV], n = 50) with few overseas strains:
EMRSA-15 (ST22-IV, n = 6). No MSSA isolates were typed.
Empirical antimicrobial therapy was effective in 75
(53.2%) PVL + ve cases and 90 (60.8%) control cases
(p = 0.191). Cases not receiving effective empiric therapy
were predominantly because of unexpected methicillin
resistance (103 cases, 83.1%, OR 9.1 [4.7-10.7 95% CI])
or as infections were polymicrobial (39 cases, 31.5%,
OR 1.3 [0.99-1.70 95% CI]). Lincosamides or linezolidTable 2 Specimen type by PVL status





All Polymicrobial 12 (8.5) 61 (41.2) <0.001
Skin/soft tissue Total 115 (81.6) 94 (63.5) <0.001
Polymicrobial 10 (8.7) 51 (54.3) <0.001
(a) Cellulitis/
wound swab
Total 15 (13.0) 55 (58.3) <0.001
Polymicrobial 5 (33.3) 33 (60.0) 0.006
(b) Abscess
soft tissue
Total 100 (87.0) 39 (41.5) <0.001
Polymicrobial 5 (5.0) 18 (46.2) <0.001
Blood Total 13 (9.2) 37 (25.0) <0.001
Polymicrobial 0 (0.0) 3 (8.1) 0.290
Bone/Joint Total 5 (3.5) 13 (8.8) 0.066
Polymicrobial 0 (0.0) 5 (38.5) 0.103
Lung Total 7 (5.0) 3 (2.0) 0.172
Renal Total 0 (0.0) 1 (0.7) 0.328
Number (%).






Methicillin 79 (56.0) 92 (62.2) 0.289
Clindamycin 124 (87.9) 106 (71.6) 0.002
Erythromycin 122 (86.5) 105 (70.9) 0.005
Mupirocin 139 (98.6) 137 (92.6) 0.040
Number (%).
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added to therapy and surgery was more often required
(73.0% versus 44.6%, p < 0.001) for PVL + ve infections
compared to controls (Table 4).
Rates of admission to high dependency unit and/or in-
tensive care unit were lower (5.7% vs 11.5%, p = 0.079)
and length of hospital stay was significantly shorter (me-
dian 5.0 vs 13.5 days, p < 0.001) for PVL + ve infections
compared to controls. Both 30 day and 1 year all cause
mortality were lower with PVL + ve infections than for
PVL-ve infections (2.8% vs 6.8%, p = 0.121; 6.4% vs
19.6%, p = 0.001) (Table 4). The 30-day mortality was
not influenced by adjunctive protein synthesis inhibitor
therapy (2.7% vs 5.3% for PVL + ve infections and con-
trols, respectively; p = 0.534). Interestingly, outcome was
not influenced by initiation of effective empiric therapy
(data not shown).
We performed a logistic regression analysis of PVL
status incorporating variables aboriginality, age, intra-
venous drug use (IVDU), community acquisition, ab-
scess, surgery and hospital length of stay. Statistically
significant independent associations with PVL were
found for aboriginality (OR 3.89, 1.83-8.25 95% CI,
p < 0.001), age (OR 0.96, 0.94-0.98 95% CI, p < 0.001),
community acquisition (OR 2.47, 1.32-4.62 95% CI,
p = 0.005), abscess (OR 3.45, 1.78-6.69 95% CI, p <
0.001), but were not found for IVDU (OR 1.67, 0.64-Table 4 Outcomes by PVL status





Initial antibiotics effective 75 (53.2) 90 (60.8) 0.191
Lincosamide/linezolid initial Txa 9 (6.4) 4 (2.8) 0.141
Lincosamide/linezolid 3db 29 (20.8) 10 (6.8) <0.001
Surgery performed 103 (73.0) 66 (44.6) <0.001
HDA/ICU admissionc 8 (5.7) 17 (11.5) 0.079
Median length of stay-days
(range)
5.0 (0–81) 13.5 (0–638) <0.001
Death within 30 days 4 (2.8) 10 (6.8) 0.121
Death within 1 year 9 (6.4) 29 (19.6) 0.001
aLincosamide or linezolid prescribed in the initial therapy.
bLincosamide or linezolid added to therapy within 3 days of isolate collection.
cHigh dependency area or intensive care unit admission.
Number (%).4.37 95% CI, p = 0.29), surgery (OR 1.77, 0.92-3.41
95% CI, p = 0.089), or hospital length of stay (OR 0.98,
0.97-1.00 95% CI, p = 0.100).
For the subset of MRSA isolates, PVL was significantly
associated with younger age (median 37 vs 50 years, p <
0.001), IVDU (p = 0.047), abscess formation (p < 0.001),
community acquisition (p < 0.001), monomicrobial infec-
tion (p < 0.001), surgery (p = 0.001), shorter length of
stay (median 3 vs 10 days, p < 0.001), but not signifi-
cantly associated with aboriginality (p = 0.091).
For the subset of invasive isolates, PVL was signifi-
cantly associated with aboriginality (p = 0.001), but not
significantly associated with age (median 41 vs 45 years,
p = 0.378), community acquisition (p = 0.171), IVDU
(p = 1.000), surgery (p = 0.433), or length of stay (median 5
vs 7 days, p = 0.300).
Discussion
We found PVL + ve S. aureus less frequently associated
with colonisation than controls (13.5% vs at least 72.9%,
respectively). A Polish group has replicated these find-
ings, showing that 85.0% of S. aureus isolates causing fu-
runculosis were PVL + ve, compared to asymptomatic
blood donors where less than 1.0% of nasal swabs
yielded positive strains [14]. Likewise, the prevalence of
PVL + ve S. aureus colonisation was 4.5% in indigenous
and rural Malaysian communities [15]. A north-east
Australian study of nasal colonisation of volunteers
and patients seeing their general practitioner with a
non-infectious illness (total sample size 699) showed
that only 1.0% (2/202) of S. aureus isolates recovered
were PVL + ve, in contrast to results showing 55.0% of
non-multiresistant MRSA and 13.0% of MSSA clinical
isolates in this region were PVL + ve [16]. Conversely,
a New Zealand study of clinical isolates versus asymp-
tomatic nasal isolates of methicillin sensitive S. aureus
found the prevalence of PVL + ve strains was no differ-
ent between these groups (37.0% vs 31.0%, p = 0.33)
[17]. Heterogeneity between such studies may be due
to differing ability of various PVL + ve clones to cause
colonisation.
Our study shows strong associations between PVL + ve
S. aureus infections and younger age, male gender, abori-
ginality, intravenous drug use and community acquired
infection compared to healthcare-associated infection.
Conversely for PVL-ve infections, healthcare-associated
epidemiological factors such as malignancy or nursing
home residency were significantly more common. These
associations were true for MRSA and MSSA. Our find-
ings support other recent reports that include MSSA: A
study from the Northern Territory of Australia of 223
PVL + ve and 255 PVL-ve S. aureus isolates (methicillin
susceptible and resistant) showed that presence of PVL
was associated with younger age, fewer co-morbidities
Boan et al. BMC Infectious Diseases  (2015) 15:10 Page 5 of 6and community onset [18]. Likewise, the aforemen-
tioned Auckland study of 124 PVL + ve and 211 PVL-ve
MSSA isolates found PVL associated with younger age,
Pacific ethnicity, surgical drainage needed and commu-
nity onset [17].
One hypothesis for the higher rates of PVL + ve S.
aureus infections amongst younger patients is that older
patients through previous exposure might have devel-
oped immunity to this toxin. Indeed, in the 1950s, a
phage 80/81 strain, now MLST ST30, became pandemic
causing outbreaks of skin and soft tissue infections and
pneumonia, especially in children [19]. A leukotoxin was
thought responsible for the virulence and transmissibility
of the strain. One postulate suggests this epidemic
had waned by the mid 1960s due to the advent of
penicillinase-resistant penicillins, but potentially the
epidemic waned from rising immunity to PVL within
the general population; supporting this concept it was
shown the toxic effect of PVL on cells could be neutralised
by immunoglobulins from patients convalescing from
infections caused by this strain [20]. Furthermore,
Gauduchon et al. have reported increasing prevalence
of antibodies to PVL with increased age, further sup-
porting an immunity hypothesis [21].
Our study shows that PVL + ve S. aureus is strongly
associated with skin and soft tissue infection, predomin-
antly abscesses. On the contrary, there is a suggestion
that PVL + ve S. aureus infrequently caused bacteraemia
or bone and joint infection. These findings have consist-
ently been reported in the literature [2,4,18,22,23] sum-
marised in the meta-analysis by Shallcross et al. [24],
and together with PVL + ve S. aureus strains tending to
affect younger patients with less co-morbidities, partly
explains the overall lower mortality from PVL + ve S.
aureus disease [17]. However, PVL + ve S. aureus strains
more often lead to relapse of infection [14] and can
cause epidemics of skin/soft tissue infections as reported
by rising Emergency Department attendances for furun-
culosis, creating significant disease burden for healthcare
systems [25]. Whilst PVL + ve S. aureus strains generally
cause a relatively benign disease spectrum, life threaten-
ing infections such as necrotising pneumonia are well
documented [6,26]. This particular manifestation of
PVL + ve S. aureus disease is rare, presumably because
additional co-factors are needed to mediate this severe
clinical picture, for example preceding viral infection [6].
Unfortunately, our sample size was too small to substan-
tiate any difference between PVL + ve and PVL-ve S.
aureus lung infections.
We believe our study failed to demonstrate any benefit
of adding a protein synthesis inhibitor (e.g. lincosamide
or linezolid) to therapy of PVL + ve S. aureus infections
because surgical drainage of abscesses, the commonest
presentation of these infections, is the mainstay of theirtreatment with antibiotics playing only a limited role in
treatment outcomes. Nonetheless, addition of a protein
synthesis inhibitor has been recommended for severe in-
vasive PVL + ve S.aureus lung disease [27].
The most significant limitation of this study is the po-
tential for selection bias. Crucially we have selected skin/
soft tissue S. aureus isolates for PVL testing because we
expected to find the PVL gene with a history of abscess
formation, based on previous literature. This finding is
borne out in the association of PVL and abscess forma-
tion in the study, however there is a risk we have biased
the PVL + ve group with abscess specimens falsely ele-
vating the percentage of skin/soft tissue to invasive in-
fections, potentially confounding bacteraemia rates or
outcome data as examples. A multivariate analysis in-
cluding abscess as a variable and subset analysis of iso-
lates sent for PVL testing for different reasons (MRSA
or invasive isolates) are attempts to account for this se-
lection bias, and many variables associated with PVL in
the primary analysis continued to show significant asso-
ciations in these analyses. Ultimately testing all S. aureus
laboratory isolates for the PVL gene would have been
more ideal. Due to the dominance of ST 93-IV in the
PVL + ve MRSA group, it is possible other factors asso-
ciated with this clone influenced outcomes in this group.
Additionally, lack of MSSA typing leads to an incom-
plete understanding of complete clonal makeup of either
group. Other limitations of the study include: the study
was performed in an adult teaching hospital in Perth,
Western Australia and might not necessarily represent
the clinical and molecular epidemiology of invasive S.
aureus infection in other jurisdictions in Australia or in
the paediatric or Aboriginal populations; the study was
non-interventional and may lack statistical power to de-
tect differences for some outcomes; clinical data relied
on hospital medical records rather than a specific case
report form and therefore we could have underestimated
the frequency of risk factors and additional data points.
Conclusions
In summary, our study demonstrates that PVL + ve MRSA
and MSSA are associated with a specific clinical picture,
predominantly pyogenic skin and soft tissue infections
which are often monomicrobial and require surgery, more
often involving patients who are younger, indigenous or
with fewer healthcare risk factors. Whether immunisation
or new therapeutic strategies can overcome this worldwide
epidemic remains to be seen.
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